Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy and safety of using lumiracoxib in the treatment of patients with knee osteoarthritis (OA)

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Celecoxib; Diclofenac; Lumiracoxib

Criteria

Inclusion Criteria:

• Primary osteoarthritis of knee (confirmed by American College of Rheumatology [ACR] criteria).

• Requirement of regular non-steroidal anti-inflammatory drug (NSAID) therapy.

Exclusion Criteria:

• Evidence of active peptic ulceration within 12 months prior to the screening visit or history of active gastrointestinal bleeding within the previous 5 years.

• Known hypersensitivity to analgesics, antipyretics, or NSAIDS (including celecoxib).

Other protocol-defined inclusion/exclusion criteria may apply